Robin M.J.M. van Geel

1.9k total citations
45 papers, 1.1k citations indexed

About

Robin M.J.M. van Geel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Robin M.J.M. van Geel has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Robin M.J.M. van Geel's work include Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (17 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). Robin M.J.M. van Geel is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Colorectal Cancer Treatments and Studies (17 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). Robin M.J.M. van Geel collaborates with scholars based in Netherlands, United States and Spain. Robin M.J.M. van Geel's co-authors include Jan H.M. Schellens, Jos H. Beijnen, Tomoko Freshwater, Suzanne Leijen, Shelonitda Rose, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Tim Demuth and Gabe S. Sonke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Robin M.J.M. van Geel

43 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin M.J.M. van Geel Netherlands 15 660 655 285 171 160 45 1.1k
Marlies H.G. Langenberg Netherlands 15 604 0.9× 749 1.1× 417 1.5× 367 2.1× 128 0.8× 34 1.3k
Haitian Quan China 17 492 0.7× 662 1.0× 383 1.3× 137 0.8× 136 0.8× 30 1.3k
Lorna Pope United Kingdom 9 567 0.9× 338 0.5× 317 1.1× 328 1.9× 187 1.2× 15 1.0k
A. Craig Lockhart United States 17 522 0.8× 477 0.7× 261 0.9× 234 1.4× 87 0.5× 49 1.0k
Maja J. De Jonge Netherlands 16 471 0.7× 449 0.7× 298 1.0× 114 0.7× 91 0.6× 43 849
Gareth Hughes United Kingdom 13 694 1.1× 627 1.0× 321 1.1× 266 1.6× 80 0.5× 22 1.3k
Heidi Steinfeldt United States 8 694 1.1× 586 0.9× 401 1.4× 254 1.5× 55 0.3× 10 1.1k
Michael E. Menefee United States 15 484 0.7× 610 0.9× 209 0.7× 181 1.1× 83 0.5× 45 1.3k
Lorelei J. Hanson United States 15 1.1k 1.7× 971 1.5× 411 1.4× 170 1.0× 224 1.4× 20 1.8k
Tomohide Tamura Japan 19 726 1.1× 522 0.8× 267 0.9× 213 1.2× 88 0.6× 44 1.2k

Countries citing papers authored by Robin M.J.M. van Geel

Since Specialization
Citations

This map shows the geographic impact of Robin M.J.M. van Geel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin M.J.M. van Geel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin M.J.M. van Geel more than expected).

Fields of papers citing papers by Robin M.J.M. van Geel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin M.J.M. van Geel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin M.J.M. van Geel. The network helps show where Robin M.J.M. van Geel may publish in the future.

Co-authorship network of co-authors of Robin M.J.M. van Geel

This figure shows the co-authorship network connecting the top 25 collaborators of Robin M.J.M. van Geel. A scholar is included among the top collaborators of Robin M.J.M. van Geel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin M.J.M. van Geel. Robin M.J.M. van Geel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Remón, Jordi, Paolo Bironzo, Francesco Cortiula, et al.. (2025). De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?. Journal of Clinical Oncology. 43(9). 1148–1156. 6 indexed citations
3.
Barnett, David, Janine Ziemons, Romy Aarnoutse, et al.. (2025). The gut microbiota during tamoxifen therapy in patients with breast cancer. Scientific Reports. 15(1). 7874–7874. 4 indexed citations
4.
Hendriks, Lizza, Kristien Winckers, Yvonne Henskens, et al.. (2024). Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer. British Journal of Cancer. 131(3). 481–490. 1 indexed citations
5.
Veerman, G., René J. Boosman, Ron H.J. Mathijssen, et al.. (2024). Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC. JTO Clinical and Research Reports. 5(4). 100656–100656. 2 indexed citations
6.
Heine, Rob ter, Michel M. van den Heuvel, Berber Piet, et al.. (2023). A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. Targeted Oncology. 18(3). 441–450. 8 indexed citations
7.
Veerman, G., Marthe S. Paats, Vivianne C. G. Tjan‐Heijnen, et al.. (2023). Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer. International Journal of Cancer. 154(2). 332–342. 7 indexed citations
8.
Stolk, Leo, et al.. (2023). Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs. Journal of Chromatography B. 1231. 123918–123918. 4 indexed citations
9.
Piet, Berber, Michel M. van den Heuvel, Catia Marzolini, et al.. (2022). Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. European Respiratory Review. 31(164). 220004–220004. 11 indexed citations
10.
Vos‐Geelen, Judith de, et al.. (2022). Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands. Journal of Cancer Research and Clinical Oncology. 149(5). 1863–1872. 4 indexed citations
11.
Mathijssen, Ron H.J., Anne‐Marie C. Dingemans, Vivianne C. G. Tjan‐Heijnen, et al.. (2022). 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels. Annals of Oncology. 33. S1067–S1068. 1 indexed citations
12.
Hendriks, Lizza, et al.. (2022). Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer. 171. 97–102. 12 indexed citations
13.
Souverein, Patrick C., Johanna H. M. Driessen, Olaf H. Klungel, et al.. (2022). Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiology. 78. 102149–102149. 4 indexed citations
14.
15.
Huijberts, Sanne C.F.A., Robin M.J.M. van Geel, Emilie M.J. van Brummelen, et al.. (2020). Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemotherapy and Pharmacology. 85(5). 917–930. 26 indexed citations
16.
Geel, Robin M.J.M. van, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, et al.. (2020). Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. British Journal of Cancer. 122(8). 1166–1174. 27 indexed citations
17.
Geel, Robin M.J.M. van, Anne‐Marie C. Dingemans, Leo Stolk, et al.. (2019). Validation of an analytical method using HPLC–MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomedical Chromatography. 34(4). e4771–e4771. 26 indexed citations
18.
Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127. 5 indexed citations
19.
Pluim, Dick, Bart Jacobs, Maarten J. Deenen, et al.. (2015). Improved Pharmacodynamic Assay for Dihydropyrimidine Dehydrogenase Activity in Peripheral Blood Mononuclear Cells. Bioanalysis. 7(5). 519–529. 13 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marlies H.G. Langenberg Breakdown of academic impact, for papers by Haitian Quan Breakdown of academic impact, for papers by Lorna Pope Breakdown of academic impact, for papers by A. Craig Lockhart Breakdown of academic impact, for papers by Maja J. De Jonge Breakdown of academic impact, for papers by Gareth Hughes Breakdown of academic impact, for papers by Heidi Steinfeldt Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by Lorelei J. Hanson Breakdown of academic impact, for papers by Tomohide Tamura
Rankless by CCL
2026